Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.

被引：3
|
作者：
Dumbrava, Ecaterina Elena
Shapiro, Geoffrey
Bendell, Johanna C.
Yap, Timothy A.
Jeselsohn, Rinath
Lepley, Denise M.
Hurley, Sabrina
Lin, Kevin K.
Liao, Michelle
Habeck, Jenn
Enke, Aaron
Hamilton, Erika P.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[4] Clovis Oncol Inc, Boulder, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3102
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer
    Li, N.
    Bu, H.
    Liu, J.
    Zhu, J.
    Zhou, Q.
    Wang, L.
    Yin, R.
    Wu, X.
    Yao, S.
    Gu, K.
    Zhang, H.
    Li, G.
    Pan, H.
    Wu, Q.
    An, R.
    Yang, X.
    Zhu, Y.
    Wan, X.
    Duan, W.
    Xiong, J.
    Wang, Y.
    Wang, Q.
    Zou, J.
    Wu, L. Y.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 159 - 159
  • [32] Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
    Yvette Drew
    Jonathan Ledermann
    Geoff Hall
    Daniel Rea
    Ros Glasspool
    Martin Highley
    Gordon Jayson
    Julieann Sludden
    James Murray
    David Jamieson
    Sarah Halford
    Gary Acton
    Zoe Backholer
    Raffaella Mangano
    Alan Boddy
    Nicola Curtin
    Ruth Plummer
    British Journal of Cancer, 2016, 114 : 723 - 730
  • [33] Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
    Drew, Yvette
    Ledermann, Jonathan
    Hall, Geoff
    Rea, Daniel
    Glasspool, Ros
    Highley, Martin
    Jayson, Gordon
    Sludden, Julieann
    Murray, James
    Jamieson, David
    Halford, Sarah
    Acton, Gary
    Backholer, Zoe
    Mangano, Raffaella
    Boddy, Alan
    Curtin, Nicola
    Plummer, Ruth
    BRITISH JOURNAL OF CANCER, 2016, 114 (07) : 723 - 730
  • [34] Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
    Leonard J. Appleman
    Jan H. Beumer
    Yixing Jiang
    Yan Lin
    Fei Ding
    Shannon Puhalla
    Leigh Swartz
    Taofeek K. Owonikoko
    R. Donald Harvey
    Ronald Stoller
    Daniel P. Petro
    Hussein A. Tawbi
    Athanassios Argiris
    Sandra Strychor
    Marie Pouquet
    Brian Kiesel
    Alice P. Chen
    David Gandara
    Chandra P. Belani
    Edward Chu
    Suresh S. Ramalingam
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 1289 - 1301
  • [35] First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.
    Plummer, R
    Middleton, M
    Wilson, R
    Jones, C
    Evans, J
    Robson, L
    Steinfeldt, H
    Kaufman, R
    Reich, S
    Calvert, AH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 208S - 208S
  • [36] Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
    Appleman, Leonard J.
    Beumer, Jan H.
    Jiang, Yixing
    Lin, Yan
    Ding, Fei
    Puhalla, Shannon
    Swartz, Leigh
    Owonikoko, Taofeek K.
    Harvey, R. Donald
    Stoller, Ronald
    Petro, Daniel P.
    Tawbi, Hussein A.
    Argiris, Athanassios
    Strychor, Sandra
    Pouquet, Marie
    Kiesel, Brian
    Chen, Alice P.
    Gandara, David
    Belani, Chandra P.
    Chu, Edward
    Ramalingam, Suresh S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (06) : 1289 - 1301
  • [37] The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-in-human phase 1/2 study
    Liu, S.
    Zhang, J.
    Chen, Z.
    Zhang, Y.
    Wang, J.
    Chen, Y.
    Chen, J.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S32 - S32
  • [38] Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
    Champiat, Stephane
    Cassier, Philippe A.
    Kotecki, Nuria
    Korakis, Iphigenie
    Vinceneux, Armelle
    Jungels, Christiane
    Blatchford, Jon
    Elgadi, Mabrouk M.
    Clarke, Nicole
    Fromond, Claudia
    Poirier, Nicolas
    Vasseur, Berangere
    Marabelle, Aurelien
    Delord, Jean-Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Erratum: Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
    Yvette Drew
    Jonathan Ledermann
    Geoff Hall
    Daniel Rea
    Ros Glasspool
    Martin Highley
    Gordon Jayson
    Julieann Sludden
    James Murray
    David Jamieson
    Sarah Halford
    Gary Acton
    Zoe Backholer
    Raffaella Mangano
    Alan Boddy
    Nicola Curtin
    Ruth Plummer
    British Journal of Cancer, 2016, 114 : e21 - e21
  • [40] A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
    Weekes, Colin
    Lockhart, A. Craig
    Lee, James J.
    Sturm, Isrid
    Cleton, Adriaan
    Huang, Funan
    Lenz, Heinz-Josef
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (09) : 2450 - 2458
12345